31 January 2005

Contents

Editorial

• Volume 6 Number 1 December 2004/January 2005

Treatment alerts

• Important new clinical data: potential early virologic failure associated with the combination antiretroviral regimen of tenofovir disoproxil fumarate, didanosine, and either efavirenz or nevirapine in HIV treatment-naive patients with high baseline viral loads

Conference reports

• 6th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV (IWADRLH) 26-28 October 2004, Washington

• Nucleoside analogue-related mitochondrial toxicity and link to lipoatrophy: effect of non-thymidine analogues abacavir and tenofovir

• Nucleosides reduce PPAR-gamma: a role for rosiglitazone without thymidine analogues?

• Potential for uridine to treat mitochondrial toxicity: still only in vitro data

• 25% patients take Kaletra on an empty stomach: dietary advice often missed at ‘centre of excellence’

• rHGH reduces central fat accumulation in adolescent lipodystrophy

• Weight loss is associated with elevated PBMC proviral DNA levels

• Coronary artery bypass graft is safe in HIV-positive patients but shows higher risk of longer term events

• Endothelial dysfunction similar in ARV-experienced and -naive patients

• Pravastatin improves lipid profiles but not endothelial function

• Indinavir impairs endothelial function without insulin resistance

• Treatment interruptions improve lipids within four weeks: IL-2 has no metabolic effect

• Improvement of lipids following switch to tenofovir

• HCV coinfection linked to discontinuing ART due to toxicity

• Restorative treatments for HIV-associated lipoatrophy

• 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 30 October-2 November 2004, Washington

• Tipranavir in treatment experienced patients: results from RESIST-1

• Reverset: first data in patients with nucleoside resistance

• Poor response with tenofovir and ddI backbone causes early study termination